Fibroblast growth factor-21 concentration in serum and synovial fluid is associated with radiographic bone loss of knee osteoarthritis. (April 2015)

• Record Type: Journal Article
• Authors: Li, Zhan-Chun; Xiao, Jie; Wang, Gang; Li, Mao-Qiang; Hu, Kong-Zu; Ma, Tao; Wang, Wei-Li; Liu, Zu-De; Zhang, Ji-Dong
• Is Part Of: Scandinavian journal of clinical & laboratory investigation. Volume 75:Number 2(2015)
• Page Start: 121
• Page End: 125
• Publication Date: 2015-04
• Subjects: Clinical biochemistry -- Periodicals; Physiology, Pathological -- Periodicals; Physiology, Experimental -- Periodicals; Medicine -- Research -- Periodicals; Clinical medicine -- Periodicals; 616.0072
• DOI: 10.3109/00365513.2014.992942
• Languages: English
• ISSNs: 0036-5513

Abstract

<abstract> <title>Abstract</title> <p>We aimed to evaluate whether FGF-21 concentration in serum and synovial fluid (SF) is associated with radiographic bone loss of knee osteoarthritis (OA). A total of 186 OA patients and 108 controls were recruited. The radiographic bone loss of knee OA was assessed by the Ahlbäck grading scale. FGF-21 concentration in serum and SF was measured by enzyme-linked immunosorbent assay (ELISA). We demonstrated that OA patients had significantly higher serum FGF-21 concentration compared with controls (204.30 [range 158.25–279.16] ng/L vs. 130.72 [range 94.93–218.03] ng/L, <italic>p</italic> &lt; 0.01). FGF-21 concentration in serum was well correlated with that in paired SF samples (<italic>r = </italic>0.668, <italic>p</italic> &lt; 0.001). In OA patients, those with a higher Ahlbäck grade had significantly higher serum and SF FGF-21 concentration (<italic>p</italic> &lt; 0.001 for both). FGF-21 concentration in serum and SF was significantly and independently associated with the Ahlbäck grade (<italic>r = </italic>0.403, <italic>p</italic> &lt; 0.001 and <italic>r = </italic>0.410, <italic>p</italic> &lt; 0.001; respectively). These findings indicated that FGF-21 might be a potential biomarker for predicting bone loss of OA. Therapeutic interventions by blocking FGF-21 signaling pathways to delay the degenerative process of OA warrants further investigations.</p> </abstract>